Cereno Scientific announces new patent issued in Mexico for Phase II drug candidate CS1
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the Company’s leading drug candidate CS1’s first patent family has obtained an issued patent in Mexico. This further strengthens the intellectual property rights for CS1, that is in late Phase II development for pulmonary arterial hypertension (PAH).“I am pleased to report that our leading drug candidate CS1 has obtained a patent issued by the Mexican authorities. Mexico is a large global pharmaceutical market, and as such an important